drugset
Drugs / iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine
last change Aug 2025 re-read 3 minutes ago

iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine

Vaccine

Developed for
hepatocellular carcinoma
Investigated by
Hangzhou Neoantigen Therapeutics Co., Ltd. · Zhejiang University

Trials 1

today NCT07123545 · Ph 1/2
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07123545 Aug 2025 → Jul 2027 expected hepatocellular carcinoma Zhejiang University Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT07123545 ↗
Modality Vaccine “iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine” NCT07123545 ↗
Route Subcutaneous “Administered subcutaneously at 0.3 mg/peptide” NCT07123545 ↗